Arcellx Q1 net loss $32.4M; CART-ddBCMA 100% ORR; doses first ACLX-001 patient

Arcellx, Inc.

2022-Q1 EPS reported -$1.25

Q1 net loss $32.4M (vs $11.3M Q1 2021); R&D expense $24.4M (+$15.9M).
Cash and marketable securities $210.9M as of Mar 31; funds operations into H2 2023.
First patient dosed in Phase 1 of ACLX-001 (ARC-SparX) for relapsed/refractory multiple myeloma.
CART-ddBCMA Phase 1 data published in Blood Advances: 100% ORR, 75% CR/sCR.
CART-ddBCMA oral abstract at ASCO June 5; data on ~25 patients to be presented.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.